These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33637618)

  • 61. Assessment of vascular leakage and its development with FFA among patients treated with intravitreal anti-VEGF due to aggressive posterior ROP.
    Ekinci DY; Vural AD; Bayramoglu SE; Onur IU; Hergunsel GO
    Int Ophthalmol; 2019 Dec; 39(12):2697-2705. PubMed ID: 30830544
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The severity and associated comorbidities of retinopathy of prematurity among micro-premature infants with birth weights less than 750 grams.
    Beck K; Young R; Read S; Harper H; Desireddi J; Harper CA
    J Neonatal Perinatal Med; 2019; 12(1):41-45. PubMed ID: 30400108
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Conbercept and Ranibizumab Pretreatments in Vitrectomy with Silicone Oil Infusion for Severe Diabetic Retinopathy.
    Yang KB; Zhang H; Li SJ; Cao JJ; Cheng LN; Lin YX; Tian ZC; Li J; Gu F; Liu ZL
    J Ocul Pharmacol Ther; 2019 Apr; 35(3):161-167. PubMed ID: 30668279
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy of intravitreal aflibercept monotherapy in retinopathy of prematurity evaluated by periodic fluorescence angiography and optical coherence tomography.
    Vural A; Perente İ; Onur İU; Eriş E; Seymen Z; Hergünsel GO; Salihoğlu Ö; Yiğit FU
    Int Ophthalmol; 2019 Oct; 39(10):2161-2169. PubMed ID: 30478752
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity compared with type I retinopathy of prematurity.
    Eftekhari Milani A; Hassanpoor N; Mousavi Mirkala M; Taheri A; Golizade A; Niyousha MR
    Int Ophthalmol; 2020 Feb; 40(2):477-482. PubMed ID: 31712928
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.
    Mintz-Hittner HA; Geloneck MM; Chuang AZ
    Ophthalmology; 2016 Sep; 123(9):1845-55. PubMed ID: 27241619
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Appropriate dose of intravitreal ranibizumab for ROP: a retrospective study.
    Chen Y; Wang S; Chen S; Chen X; Han L; Zhong Q; Zhang K
    BMC Ophthalmol; 2022 Jun; 22(1):271. PubMed ID: 35729540
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Analysis of the Recurrence of Plus Disease after Intravitreal Ranibizumab as a Primary Monotherapy for Severe Retinopathy of Prematurity.
    Arámbulo O; Dib G; Iturralde J; Brito M; Fortes Filho JB
    Ophthalmol Retina; 2018 Aug; 2(8):858-863. PubMed ID: 31047540
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: efficacy, anatomical outcomes and safety.
    Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M
    Br J Ophthalmol; 2019 Sep; 103(9):1332-1336. PubMed ID: 30514709
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy comparison of intravitreal injections of conbercept and ranibizumab for severe proliferative diabetic retinopathy.
    Lu Q; Lu L; Chen B; Chen W; Lu P
    Can J Ophthalmol; 2019 Jun; 54(3):291-296. PubMed ID: 31109466
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Fluorescein angiographic features post-intravitreal bevacizumab for retinopathy of prematurity: can they support rescue laser photocoagulation to the avascular retina.
    Gonzalez A; Agarwal-Sinha S
    Can J Ophthalmol; 2020 Oct; 55(5):373-381. PubMed ID: 32835673
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy evaluation of intravitreal ranibizumab therapy for three types of retinopathy of prematurity.
    Zou Q; Zhu YQ; Zhang FJ; Liu QP
    Int J Ophthalmol; 2022; 15(5):753-759. PubMed ID: 35601165
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Intraocular pressure effect of anti-vascular endothelial growth factor injection for aggressive posterior retinopathy of prematurity.
    Ozdemir O; Arman A; Tayman C
    Graefes Arch Clin Exp Ophthalmol; 2021 Nov; 259(11):3469-3476. PubMed ID: 34151383
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [The clinical study on intravitreous injection of ranibizumab for aggressive posterior retinopathy of prematurity].
    Tian R; Zhang G; Tang S; Guo J; Tan W
    Zhonghua Yan Ke Za Zhi; 2015 Nov; 51(11):822-5. PubMed ID: 26850583
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.
    Mintz-Hittner HA; Kennedy KA; Chuang AZ;
    N Engl J Med; 2011 Feb; 364(7):603-15. PubMed ID: 21323540
    [TBL] [Abstract][Full Text] [Related]  

  • 76. LONG-TERM EFFECTS OF ANTI-VEGF MONOTHERAPY FOR RETINOPATHY OF PREMATURITY ON THE RETINAL AND REFRACTIVE DEVELOPMENT OF EYE.
    Sukgen EA; Atalay HT; Özdek Ş
    Retina; 2022 Nov; 42(11):2194-2202. PubMed ID: 35962999
    [TBL] [Abstract][Full Text] [Related]  

  • 77. New trends in intravitreal anti-VEGF therapy for ROP.
    Beccasio A; Mignini C; Caricato A; Iaccheri B; Di Cara G; Verrotti A; Cagini C
    Eur J Ophthalmol; 2022 May; 32(3):1340-1351. PubMed ID: 35040348
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
    Han J; Kim SE; Lee SC; Lee CS
    Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey.
    Yetik H; Gunay M; Sirop S; Salihoglu Z
    Graefes Arch Clin Exp Ophthalmol; 2015 Oct; 253(10):1677-83. PubMed ID: 25501298
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up.
    Isaac M; Tehrani N; Mireskandari K;
    Eye (Lond); 2016 Mar; 30(3):333-41. PubMed ID: 26869159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.